A Phase III Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Patients With Chronic Hepatitis C Infection Who Were Non-responders to Previous Treatment.
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2017
At a glance
- Drugs Vaniprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 31 Aug 2018 Biomarkers information updated
- 02 Mar 2016 Results of this and other trial (see profile 203801) published in the Journal of Gastroenterology and Hepatology
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.